GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (NAS:IMNN) » Definitions » Cyclically Adjusted PS Ratio

Imunon (Imunon) Cyclically Adjusted PS Ratio : (As of May. 26, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Imunon Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Imunon Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Imunon's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Cyclically Adjusted PS Ratio Chart

Imunon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.97 0.45 2.43 0.42 -

Imunon Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Imunon's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Imunon's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imunon's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Imunon's Cyclically Adjusted PS Ratio falls into.



Imunon Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Imunon's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Imunon's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Imunon Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.506 100.560 1.974
201409 1.506 100.428 1.976
201412 1.136 99.070 1.511
201503 1.316 99.621 1.741
201506 1.250 100.684 1.636
201509 1.136 100.392 1.491
201512 1.126 99.792 1.487
201603 1.126 100.470 1.477
201606 1.087 101.688 1.409
201609 0.940 101.861 1.216
201612 0.926 101.863 1.198
201703 1.126 102.862 1.443
201706 0.283 103.349 0.361
201709 0.233 104.136 0.295
201712 0.109 104.011 0.138
201803 0.106 105.290 0.133
201806 0.106 106.317 0.131
201809 0.105 106.507 0.130
201812 0.104 105.998 0.129
201903 0.098 107.251 0.120
201906 0.091 108.070 0.111
201909 0.087 108.329 0.106
201912 0.073 108.420 0.089
202003 0.073 108.902 0.088
202006 0.063 108.767 0.076
202009 0.055 109.815 0.066
202012 0.049 109.897 0.059
202103 0.073 111.754 0.086
202106 0.022 114.631 0.025
202109 0.022 115.734 0.025
202112 0.022 117.630 0.025
202203 0.022 121.301 0.024
202206 0.018 125.017 0.019
202209 0.018 125.227 0.019
202212 0.014 125.222 0.015
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Imunon  (NAS:IMNN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Imunon Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Imunon's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Imunon (Imunon) Business Description

Industry
Traded in Other Exchanges
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
Executives
James E Dentzer director C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Le Goff Corinne director, officer: President and CEO 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Michael H Tardugno officer: Chief Executive Offier 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046-2364
Frederick J. Fritz director C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Kardaras Constantine John officer: Chief Accounting Officer C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE100, LAWRENCEVILLE NJ 08648
Christine A Pellizzari director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Stacy Lindborg director C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Donald P Braun director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Alberto R Martinez director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Jeffrey Wayne Church officer: Chief Financial Officer
Robert W Hooper director C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Andreas Voss director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Egwu, Inc. Fka Egen, Inc. 10 percent owner 601 GENOME WAY, SUITE 3400, HUNTSVILLE AL 35806
Khursheed Anwer officer: Chief Scientific Officer C/O CELSION CORPORATION, 997 LENOX DRVIE, SUITE 100, LAWRENCEVILLE NJ 08648
Gregory L Weaver director 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107